Gemcitabine for the treatment of metastatic breast cancer

Breast cancer - gemcitabine: review decision - May 2010 information

Breast cancer - gemcitabine: review proposal - March 2010 information

Appendix A - a full list of the organisations contacted for this review (PDF 59 KB)

Appendix B - proposal paper considered by the Institute's Guidance Executive (PDF 112 KB)

Breast cancer - gemcitabine: Final appraisal determination information

Final appraisal determination (PDF 60 KB)

Response to consultee, commentator and public comments on the ACD (PDF 153 KB)

Royal College of Nursing (PDF 22 KB)

Consultee and commentator comments on the ACD

Welsh Assembly Government (PDF 45 KB)

Southampton Health Technology Assessment Centre (PDF 24 KB)

Royal College of Radiologists (PDF 21 KB)

Royal College of Physicians (PDF 45 KB)

Royal College of Pathologists (PDF 14 KB)

Roche (PDF 26 KB)

National Collaborating Centre for Cancer (PDF 11 KB)

National Cancer Research Institute (PDF 73 KB)

Eli Lilly and Company Ltd (PDF 95 KB)

Department of Health (PDF 12 KB)

Cancerbackup (PDF 43 KB)

British Oncology Pharmacy Association (PDF 48 KB)

Breakthrough Breast Cancer (PDF 321 KB)

Gemcitabine for the treatment of metastatic breast cancer (appraisal consultation document) information

Evidence considered

Pre meeting brief (PDF 50 KB)

Breast cancer - gemcitabine: evidence review group report (PDF 384 KB)

NICE clarification and responses

Manufacturer response (PDF 157 KB)

NICE clarification letter (PDF 32 KB)

Expert written personal statements

Wood (PDF 32 KB)

Verrill (PDF 36 KB)

Makris (PDF 21 KB)

Leadbeater (PDF 30 KB)

Heys (PDF 33 KB)

Breast cancer - gemcitabine - letter to consultees and commentators informing transer to STA process (PDF 26 KB)

Breast Cancer - gemcitabine, draft scope (PDF 28 KB)

Breast Cancer - gemcitabine, provisional matrix of consultees and commentators (PDF 25 KB)